nach oben

Reactions Weekly

Erschienen in:

01.07.2010 | Case report

Imatinib

Halo nevi: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Excerpt

A 46-year-old man started receiving imatinib 400 mg/m² daily for dermatofibrosarcoma protuberans [route of administration not stated]. After 8 weeks, he developed facial oedema mainly on his peri-ocular area. At the next follow-up, he had depigmentation around some nevi on his back [time to reaction onset not stated]. In a few weeks, he had diffuse halo nevi. After 9 months, imatinib was discontinued as his tumour had became surgically treatable. His oedema resolved, but at latest follow-up, 3 months after imatinib cessation, his halo nevi persisted. …

Fava P, Stroppiana E, Savoia P, Bernengo MG.Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient. Journal of the European Academy of Dermatology and Venereology 24: 244-5, No. 2, Feb 2010 - Italy

Titel: Imatinib
Halo nevi: case report
Publikationsdatum: 01.07.2010
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2010
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.2165/00128415-201013110-00096

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Imatinib

Halo nevi: case report

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Ramipril

Thiamazole

Etanercept/infliximab

Disulfiram interaction

Pramipexole

Biperiden